

REFERENCES

- Alberts, C.J., Clifford, G.M., Georges, D., Negro, F., Lesi, O.A., Hutin, Y.J-F. and de Martel, C. (2022). Worldwide Prevalence of Hepatitis B Virus and Hepatitis C Virus among Patients with Cirrhosis at country, region, and Global levels: a Systematic Review. *The Lancet Gastroenterology & Hepatology*. doi:[https://doi.org/10.1016/s2468-1253\(22\)00050-4](https://doi.org/10.1016/s2468-1253(22)00050-4).
- American Association for the Study of Liver Diseases (2018). Update on prevention, diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Hepatology*, [online] 67(4), pp.1560–1599. doi:<https://doi.org/10.1002/hep.29800>.
- American Association for the Study of Liver Diseases, Zhou, J., Wang, L., Wu, X., Chen, Y., Piao, H., Lu, L., Jiang, W., Xu, Y., Feng, B., Nan, Y., Xie, W., Chen, G.-F., Zheng, H., Li, H., Ding, H., Liu, H., Fudong Lv, Shao, C. and Wang, T. (2016). New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients before and after Treatment. 65(5), pp.1438–1450. doi:<https://doi.org/10.1002/hep.29009>.
- Arjmand, A., Tsipouras, M.G., Tzallas, A.T., Forlano, R., Manousou, P. and Giannakeas, N. (2020). Quantification of Liver Fibrosis—A Comparative Study. *Applied Sciences*, 10(2), p.447. doi:<https://doi.org/10.3390/app10020447>.
- Chadha, N. and Sterling, R.K. (2022). Noninvasive Tests for Liver Fibrosis in Chronic Hepatitis B Virus. *Current Hepatology Reports*, 21(4), pp.68–75. doi:<https://doi.org/10.1007/s11901-022-00592-2>.
- Chang, M. and Liaw, Y. (2022). Hepatitis B Flare in Hepatitis B E Antigen-Negative Patients: a Complicated Cascade of Innate and Adaptive Immune Responses. *International Journal of Molecular Sciences*, 23(3), pp.1552–1552. doi:<https://doi.org/10.3390/ijms23031552>.
- Chen, P., Xie, Q., Lu, X., Yu, C., Xu, K., Ruan, B., Cao, H., Gao, H. and Li, L. (2017). Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA. *Medicine*, 96(33), p.e7766. doi:<https://doi.org/10.1097/md.0000000000007766>.
- Chien, R.-N. and Liaw, Y.-F. (2022). Current Trend in Antiviral Therapy for Chronic

Hepatitis B. *Viruses*, 14(2), p.434. doi:<https://doi.org/10.3390/v14020434>.

Croagh, C.M. and Lubel, J.S. (2014). Natural History of Chronic Hepatitis B: Phases in a Complex Relationship. *World Journal of Gastroenterology : WJG*, [online] 20(30), pp.10395–10404. doi:<https://doi.org/10.3748/wjg.v20.i30.10395>.

Elpek, G.Ö. (2014). Cellular and Molecular Mechanisms in the Pathogenesis of Liver fibrosis: an Update. *World Journal of Gastroenterology*, 20(23), p.7260. doi:<https://doi.org/10.3748/wjg.v20.i23.7260>.

European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. *Journal of Hepatology*, [online] 67(2), pp.370–398. doi:<https://doi.org/10.1016/j.jhep.2017.03.021>.

Fisicaro, P., Barili, V., Rossi, M., Montali, I., Vecchi, A., Acerbi, G., Laccabue, D., Zecca, A., Penna, A., Missale, G., Ferrari, C. and Boni, C. (2020). Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. *Frontiers in Immunology*, 11. doi:<https://doi.org/10.3389/fimmu.2020.00849>.

Fouad, R., Musa, S., Sabry, D., Salama, A., Abdel Alem, S., Atef, M. and Zayed, N. (2020). Analysis of Clinical and Virologic Features in Hepatitis B E Antigen (HbeAg)-negative and HbeAg-positive Egyptian Chronic Hepatitis B Patients. *African Health Sciences*, 20(2), pp.649–655. doi:<https://doi.org/10.4314/ahs.v20i2.13>.

Global Burden of Disease collaborators, Ippolito, H., Abubaker Ali, H., Adegboye, O.A., Adnani, Q.E.S., Advani, S.M., Afzal, M.S., Afzal, S., Aghaie Meybodi, M., Ahadinezhad, B., Ahinkorah, B.O., Ahmad, S., Ahmad, T., Ahmadi, S., Ahmed, H., Ahmed, M.B., Ahmed Rashid, T., Akalu, G.T., Aklilu, A. and Akram, T. (2022). Global, regional, and National Burden of Hepatitis B, 1990–2019: a Systematic Analysis for the Global Burden of Disease Study 2019. *The Lancet Gastroenterology & Hepatology*, [online] 7(9), pp.796–829. doi:[https://doi.org/10.1016/S2468-1253\(22\)00124-8](https://doi.org/10.1016/S2468-1253(22)00124-8).

Han, J., Guo, Y., Zhang, X., Zhang, Y., Sun, J., He, J., Mao, R., Huang, Y. and Zhang, J. (2023). Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients after Long-Term Therapy with Nucleos(t)ide Analogs. *The Turkish Journal*

- Hu, M., Liao, G., Wei, S., Qian, Z., Chen, H., Xia, M., Xie, Q. and Peng, J. (2023). Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: a Multi-center Retrospective Cohort Study. *Infectious Diseases and Therapy*, 12(2), pp.637–647. doi:<https://doi.org/10.1007/s40121-022-00757-y>.
- Iannacone, M. and Guidotti, L.G. (2021). Immunobiology and Pathogenesis of Hepatitis B Virus Infection. *Nature Reviews Immunology*, 22. doi:<https://doi.org/10.1038/s41577-021-00549-4>.
- Jeanu, C., Ungureanu, B., Săndulescu, D., Gheonea, I., Tudorașcu, D., Ciurea, M. and Purcărea, V. (2015). Quantification of Liver Fibrosis in Chronic Hepatitis B Virus Infection. *Journal of Medicine and Life*, [online] 8(3), pp.285–290. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556907/>.
- Kau, A., Johannes Vermehren and Sarrazin, C. (2008). Treatment Predictors of a Sustained Virologic Response in Hepatitis B and C. *Journal of Hepatology*, 49(4), pp.634–651. doi:<https://doi.org/10.1016/j.jhep.2008.07.013>.
- Khanam, A., Saleeb, P.G. and Kottlil, S. (2021). Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? *Cells*, [online] 10(5), p.1097. doi:<https://doi.org/10.3390/cells10051097>.
- Kisseleva, T. and Brenner, D. (2020). Molecular and Cellular Mechanisms of Liver Fibrosis and Its Regression. *Nature Reviews Gastroenterology & Hepatology*. doi:<https://doi.org/10.1038/s41575-020-00372-7>.
- Korean Association for the Study of the Liver (2019). KASL Clinical Practice Guidelines for Management of Chronic Hepatitis B. *Clinical and Molecular Hepatology*, [online] 25(2), pp.93–159. doi:<https://doi.org/10.3350/cmh.2019.1002>.
- Koyuncuer, A. (2014). Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. *Science Journal of Clinical Medicine*, 3(6), pp.117–117. doi:<https://doi.org/10.11648/j.sjcm.20140306.14>.



- Li, N., Xu, Ji.H., Si, C. and Xu, Y. (2015). Relationship between Virological Response and FIB-4 Index in Chronic Hepatitis B Patients with Entecavir Therapy. *World Journal of Gastroenterology*, 21(43), p.12421. doi:<https://doi.org/10.3748/wjg.v21.i43.12421>.
- Liaw, Y.-F. and Chu, C.-M. (2009). Hepatitis B Virus Infection. *The Lancet*, [online] 373(9663), pp.582–592. doi:[https://doi.org/10.1016/S0140-6736\(09\)60207-5](https://doi.org/10.1016/S0140-6736(09)60207-5).
- Lin, C. and Kao, J. (2013). Hepatitis B Viral Factors and Treatment Responses in Chronic Hepatitis B. *Journal of the Formosan Medical Association*, 112(6), pp.302–311. doi:<https://doi.org/10.1016/j.jfma.2013.02.001>.
- Liu, C., Chang, L., Jia, T., Guo, F., Zhang, L., Ji, H., Zhao, J. and Wang, L. (2017). Real-time PCR assays for hepatitis B virus DNA quantification may require two different targets. *Virology Journal*, 14(1). doi:<https://doi.org/10.1186/s12985-017-0759-8>.
- Lovett, G.C., Nguyen, T., Iser, D.M., Holmes, J.A., Chen, R., Demediuk, B., Shaw, G., Bell, S.J., Desmond, P.V. and Thompson, A.J. (2017). Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. *World Journal of Hepatology*, 9(1), p.48. doi:<https://doi.org/10.4254/wjh.v9.i1.48>.
- Muljono, D. (2017). Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian Journal of Hepato-Gastroenterology*, [online] 7(1), pp.55–59. doi:<https://doi.org/10.5005/jp-journals-l0018-1212>.
- Nguyen, M.H., Wong, G., Gane, E., Kao, J.-H. and Dusheiko, G. (2020). Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. *Clinical Microbiology Reviews*, [online] 33(2). doi:<https://doi.org/10.1128/CMR.00046-19>.
- Parikh, P., Ryan, J.D. and Tsochatzis, E.A. (2017). Fibrosis Assessment in Patients with Chronic Hepatitis B Virus (HBV) Infection. *Annals of Translational Medicine*, [online] 5(3), pp.40–40. doi:<https://doi.org/10.21037/atm.2017.01.28>.
- Peng, J., Luo, K., Zhu, Y., Guo, Y., Zhang, L. and Hou, J. (2003). Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen. *Chinese Medical Journal*, [online] 116(9), pp.1312–1317. Available at: <https://pubmed.ncbi.nlm.nih.gov/14527355/> [Accessed 17 Mar. 2024].



- Rabbi, F.J., Rezwan, Md.K. and Shirin, T. (2008). HBeAg/anti-HBe, alanine aminotransferase and HBV DNA. *Bangladesh Medical Research Council Bulletin*, 34(2), pp.39–43. doi:<https://doi.org/10.3329/bmrcb.v34i2.1173>.
- Roehlen, N., Crouchet, E. and Baumert, T.F. (2020). Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. *Cells*, [online] 9(4). doi:<https://doi.org/10.3390/cells9040875>.
- Sabeena, S. and Ravishankar, N. (2022). Horizontal Modes of Transmission of Hepatitis B Virus (HBV): A Systematic Review and Meta-Analysis. *Iranian Journal of Public Health*. doi:<https://doi.org/10.18502/ijph.v51i10.10977>.
- Seeger, C. and Mason, W.S. (2015). Molecular Biology of Hepatitis B Virus Infection. *Virology*, [online] 479-480, pp.672–686. doi:<https://doi.org/10.1016/j.virol.2015.02.031>.
- Seto, W.-K., Lo, Y.-R., Pawlotsky, J.-M. and Yuen, M.-F. (2018). Chronic Hepatitis B Virus Infection. *The Lancet*, 392(10161), pp.2313–2324. doi:[https://doi.org/10.1016/s0140-6736\(18\)31865-8](https://doi.org/10.1016/s0140-6736(18)31865-8).
- Shi, Y. and Zheng, M. (2020). Hepatitis B Virus Persistence and Reactivation. *BMJ*, p.m2200. doi:<https://doi.org/10.1136/bmj.m2200>.
- Sun, F., Li, Z., Hu, L., Deng, W., Jiang, T., Wang, S., Bi, X., Lu, H., Yang, L., Lin, Y., Zeng, Z., Shen, G., Liu, R., Chang, M., Wu, S., Gao, Y., Hao, H., Xu, M., Chen, X. and Zhang, L. (2022). Sustained Viral Response and Relapse after Discontinuation of Oral Antiviral Drugs in HBeAg-positive Patients with Chronic Hepatitis B Infection. *Frontiers in Immunology*, 13. doi:<https://doi.org/10.3389/fimmu.2022.1082091>.
- Sun, Y.-M., Chen, S.-Y. and You, H. (2020). Regression of Liver fibrosis: Evidence and Challenges. *Chinese Medical Journal*, 133(14), pp.1696–1702. doi:<https://doi.org/10.1097/cm9.0000000000000835>.
- Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K.-M., Hwang, J.P., Jonas, M.M., Brown, R.S., Bzowej, N.H. and Wong, J.B. (2018). Update on prevention, diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Hepatology*, [online] 67(4), pp.1560–1599. doi:<https://doi.org/10.1002/hep.29800>.



- The Asian Pacific Association for the Study of the Liver, Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L.Y., Chen, C.J., Gane, E., Hou, J.L., Jafri, W., Jia, J., Kim, J.H., Lai, C.L., Lee, H.C., Lim, S.G., Liu, C.J., Locarnini, S., Al Mahtab, M., Mohamed, R., Omata, M. and Park, J. (2015). Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: a 2015 Update. *Hepatology International*, 10(1), pp.1–98. doi:<https://doi.org/10.1007/s12072-015-9675-4>.
- Tu, T., Budzinska, M.A., Shackel, N.A. and Urban, S. (2017). HBV DNA Integration: Molecular Mechanisms and Clinical Implications. *Viruses*, [online] 9(4), p.75. doi:<https://doi.org/10.3390/v9040075>.
- Wong, V., Chan, H. and Wong, G. (2017). *Liver Fibrosis Progression in Patients with Chronic Hepatitis B: a Prospective Study with Paired Transient Elastography*. [online] Available at: <https://www.hkmj.org/system/files/hkm1708sp5p23.pdf> [Accessed 22 Feb. 2024].
- World Health Organization (2021). *Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted infections, 2021*. [online] www.who.int. Available at: <https://www.who.int/publications/i/item/9789240027077>.
- World Health Organization (2022). *Global Guidance on Criteria and Processes for validation: Elimination of mother-to-child Transmission of HIV, Syphilis and Hepatitis B Virus*. [online] www.who.int. Available at: <https://www.who.int/publications/i/item/9789240039360>.
- Wu, J.-F., Song, S.-H., Lee, C.-S., Chen, H.-L., Ni, Y.-H., Hsu, H.-Y., Wu, T.-C. and Chang, M.-H. (2018). Clinical Predictors of Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection from Children to Adults. *The Journal of Infectious Diseases*, [online] 217(9), pp.1408–1416. doi:<https://doi.org/10.1093/infdis/jiy048>.
- Wu, Y.-L., Shen, C.-L. and Chen, X.-Y. (2019). Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. *World Journal of Clinical Cases*, [online] 7(14), pp.1784–1794. doi:<https://doi.org/10.12998/wjcc.v7.i14.1784>.
- Xiao, L., Xian, J., Li, Y., Geng, A., Yang, X., Han, L. and Xu, H. (2014). Parameters Associated with Significant Liver Histological Changes in Patients with Chronic



Hepatitis B. *ISRN Gastroenterology (Print)*, [online] 2014, pp.1–6.

doi:<https://doi.org/10.1155/2014/913890>.

Xu, Y., Wu, X.-N., Shi, Y.-W., Wei, W., Yang, A.-T., Sun, Y.-M., Zhao, W.-S. and You, H. (2015). Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3rd Month Virological Response to Entecavir Therapy. *Chinese Medical Journal*, [online] 128(14), pp.1867–1872. doi:<https://doi.org/10.4103/0366-6999.160488>.

Zhong, S., Zhang, T., Tang, L. and Li, Y. (2021). Cytokines and Chemokines in HBV Infection. *Frontiers in Molecular Biosciences*, 8. doi:<https://doi.org/10.3389/fmolb.2021.805625>.